Pharma and biotech companies gain unprecedented, on-demand access to socio-behavioral insights to improve access to therapy and support for vulnerable patients
Clarify Health, the leading cloud analytics company delivering real-world insights to healthcare and life sciences organizations, launched new applications of its anonymized patient-level social determinants of health (SDoH) insights to help life sciences companies on their patient-first missions. With real world evidence (RWE) software products, Clarify Growth and Clarify Portfolio, pharmaceutical and biotechnology companies gain the unprecedented ability to explore and understand how patients’ journeys, treatment decisions, and outcomes are impacted by non-medical factors such as race, income, transportation access, housing stability, education level, health literacy, and propensity to exercise.
“The pharmaceutical industry has a critical role to play in advancing health equity,” said Jean Drouin, MD, CEO, Clarify Health. “Clarify’s real-world insights provide a window into how medical care and social and behavioral determinants of health interconnect to influence each patient’s journey. Our RWE products help evaluate health disparities, such as discrepancies between patients who are diagnosed and those who are treated based on race and socioeconomic status, to ensure eligible patients have equal access to treatment.”
Clarify has access to vast sources of clinically relevant consumer data for all Americans. With this launch, its life sciences products draw upon an expanded and extensive set of individual-level, de-identified SDoH factors, which are linked together with government and commercial claims, clinical, and prescription and dispensing data. Its cloud software uses machine learning to interrogate these longitudinal patient journeys and identify real-world health disparities within patient cohorts. Clarify’s on-demand insights help its customers ensure that their healthcare provider outreach programs and patient assistance programs are the best fit to get the right treatment to the right patient at the right time.
“Our pharma and biotech customers are increasingly asking for socio-behavioral insights to ensure patients with heath disparities get accurately diagnosed and get on the right therapy,” says Todd Gottula, President, Clarify Health. “Our patented AI insights platform delivers the nation’s largest collection of de-identified patient journeys, enhanced with the greatest breadth of individual-level SDoH factors. Drawing upon these journeys, our software precisely pinpoints the needs of any patient cohort and surfaces the most impactful real-world opportunities to improve outcomes.”
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.
